؊/؊ or Act1 ؊/؊ mice). However, Lcn2 ؊/؊ mice were completely resistant to OPC, comparably to wild-type (WT) mice. Moreover, Lcn2 deficiency mediated protection from OPC induced by steroid immunosuppression. Therefore, despite its potent regulation during C. albicans infection, Lcn2 is not required for immunity to mucosal candidiasis.
O ropharyngeal candidiasis (OPC; thrush) is an opportunistic infection associated with CD4
ϩ T cell loss and is caused by the commensal fungus Candida albicans. Individuals with HIV/ AIDS are particularly prone to this disease, and OPC is considered an AIDS-defining illness (1, 2) . In addition, OPC is common in patients taking immunodepleting chemotherapy, infants and the elderly, and patients with congenital immunodeficiencies, such as hyper-IgE syndrome (HIES) (3) . OPC exhibits considerable morbidity and can cause impaired nutrition due to odynophagia (pain with swallowing) and failure to thrive in infants. To date, there are no clinically available vaccines for C. albicans, or indeed for any fungal pathogens (4, 5) .
The cytokine interleukin 17 (IL-17; also known as IL-17A) is tightly associated with immunity to OPC (6) . Mice lacking either IL-17 receptor subunit (IL-17RA and IL-17RC) are highly susceptible to OPC. Similarly, mice lacking IL-23 (either the IL-12p40 or the IL-23p19 subunit), a cytokine that induces IL-17-producing cells, are also susceptible (7) (8) (9) . In agreement with the findings for mice, humans with mutations in IL-17RA or its ligand IL-17F suffer from chronic mucocutaneous candidiasis (CMC), characterized by both OPC and dermal candidiasis (10) . In addition, neutralizing anti-IL-17 antibodies in autoimmune regulator (AIRE) deficiency or in some thymomas are linked to susceptibility to OPC (11, 12) . IL-17 signals through an adaptor protein, Act1 (also known as CIKS) (13) , and Act1-deficient humans were recently identified on the basis of their susceptibility to recurrent CMC (14) . Antibodies against IL-17 and its receptor are currently in clinical trials for the treatment of autoimmune diseases such as psoriasis and rheumatoid arthritis (15) (16) (17) (18) , but the potential adverse effects of these therapies are still not well defined. On the basis of the evidence outlined above, OPC and CMC are obviously of particular concern for patients taking anti-IL-17 therapies. In fact, a recent report indicates that patients on anti-tumor necrosis factor (anti-TNF) drugs for inflammatory bowel disease show an increased risk of candidiasis, which had not been previously recognized (19) .
Although IL-17 signaling is clearly essential for immunity to OPC, the downstream mechanisms by which IL-17 mediates immunity to this fungus remain largely unknown. IL-17 signaling induces a program of gene expression associated with innate immune responses, including cytokines (IL-6, granulocyte colonystimulating factor [G-CSF]), chemokines (CXCL1, CXCL2, CCL20), and antimicrobial peptides (␤-defensins and S100A8/9) (13). One of the most strongly induced IL-17 target genes encodes lipocalin 2 (Lcn2), which is regulated at the transcriptional level by IL-17 either alone or in conjunction with TNF-␣ (20) (21) (22) . IL-17 signaling in a variety of cell types induces Lcn2 expression (20) , and lcn2 mRNA is one of many IL-17 signature genes induced in the oral mucosa following C. albicans infection (7).
Lipocalin 2, also known as 24p3, uterocalin, or neutrophil gelatinase-associated lipocalin (NGAL), is an acute-phase protein produced by the liver and also by mesenchymal and epithelial cells in response to inflammatory cytokines. Lcn2 plays a key role in preventing iron acquisition by bacteria that use catecholate-type siderophores (23, 24) . Accordingly, Lcn2
Ϫ/Ϫ mice are highly susceptible to infection by Escherichia coli and Klebsiella pneumoniae (25) (26) (27) , bacterial species that use this type of iron-scavenging system. However, the role of Lcn2 in mediating immunity to fungi has not been a focus of investigation. Accordingly, in this study, we evaluated the role of Lcn2 in immunity to mucosal C. albicans infection. Surprisingly, Lcn2 was not required for the host defense against OPC, even though it was strongly upregulated in an IL-17-dependent manner following Candida infection. Moreover, Lcn2 deficiency appeared to mediate protection from oral thrush induced by immunosuppression, suggesting an immunoregulatory role for this protein.
MATERIALS AND METHODS
Mice used and oropharyngeal candidiasis model. Mice were on the C57BL/6 background and were age and sex matched. IL-23p19 Ϫ/Ϫ mice were provided by Genentech (South San Francisco, CA), and IL-17RA Ϫ/Ϫ mice were from Amgen (Seattle, WA). Lcn2 Ϫ/Ϫ mice were a kind gift from Tak Mak, University of Toronto, and have been described previously (25, 27) . Act1 Ϫ/Ϫ mice have been described previously (28) . All mice were housed under specific-pathogen-free (SPF) conditions. The genotypes of all mice were verified by PCR of ear biopsy specimens. Mice aged 7 to 10 weeks (n, 3 to 10 per experiment) were inoculated sublingually with a 0.0025-g cotton ball saturated with a C. albicans (strain CAF2-1) suspension of 2 ϫ 10 7 CFU/ml for 75 min under anesthesia, as described previously (29) . If indicated, mice were administered cortisone acetate intraperitoneally (i.p.) at 225 mg/kg of body weight at days Ϫ1, ϩ1, and ϩ3 relative to infection. The oral cavity was swabbed before each infection, and swabs were plated on YPD-AMP (yeast extract-peptone-dextrose agar plus ampicillin) agar plates to verify the absence of Candida. Mice were weighed daily. After sacrifice, the tongue of each mouse was homogenized on a gentleMACS Dissociator (Miltenyi Biotec, Auburn, CA), and serial dilutions were plated on YPD-AMP agar in triplicate for colony enumeration. Data were analyzed by GraphPad Prism (version 5) by using t tests with the Mann-Whitney correction (a P value of Ͻ0.05 was considered significant). Protocols were approved by the University of Pittsburgh IACUC.
Histology. Tongue tissue was prepared for histology by the Research Histology Services core of the University of Pittsburgh. Samples were stained with periodic acid-Schiff stain (PAS) and were imaged at a magnification of ϫ10 to ϫ40.
RNA preparation and real-time reverse transcriptase PCR. RNA was extracted with RNeasy kits, and cDNA was synthesized with a SuperScript III first-strand synthesis system (Invitrogen). Relative quantification of gene expression was carried out by real-time PCR with SYBR green (Quanta BioSciences, Gaithersburg, MD) and normalization to the expression of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene. All samples were analyzed in triplicate. Primers were from SABiosciences (Qiagen). Results were analyzed on an Applied Biosystems (Carlsbad, CA) 7300 real-time PCR system.
RESULTS

Lcn2 is induced in an IL-17R-dependent manner during OPC.
To evaluate Lcn2 expression during OPC, we infected C57BL/6 mice orally with Candida albicans (strain CAF2-1), using a standard OPC infection model with 75 min of sublingual exposure to C. albicans strain CAF2-1 (29) . As controls, we subjected wildtype (WT) mice administered high-dose cortisone, IL-17RA Ϫ/Ϫ mice, and Act1 Ϫ/Ϫ mice to OPC (28) , since the IL-23/IL-17 pathway is known to be essential for immunity to oral candidiasis (7). We then measured the C. albicans load in the tongue at either day 2 or day 4 postinfection by plating serial dilutions of tongue homogenates onto YPD-AMP agar plates. At day 2, all animals, including WT mice, had similarly high fungal burdens, a result comparable to historical data with this model (Fig. 1A) (7) . By day 4, WT mice had fully cleared the infection, whereas IL-17RA Ϫ/Ϫ and Act1 Ϫ/Ϫ mice still had significant oral fungal loads. Weight loss measurements paralleled the fungal load data; WT mice fully recovered their original weight by day 4, correlating with fungal clearance, but IL-17RA Ϫ/Ϫ mice, Act1 Ϫ/Ϫ mice, and cortisonetreated WT mice still showed reduced weight and persistent fungal Ϫ/Ϫ and Act1 Ϫ/Ϫ mice. The expression of lcn2 at day 2 or 4 postinfection was assessed by quantitative PCR of RNA from tongue tissue from the indicated mice; the value obtained was normalized to that for GAPDH expression. Each result is the fold change from expression in sham-treated mice at the same time point. The asterisk indicates a significant difference from results for sham-treated mice (P, Ͻ0.05) by the t test with the Mann-Whitney correction. loads ( Fig. 1A and B) . We then measured the expression of lcn2 mRNA from tongues taken from these mice at day 2 and day 4 postinfection. lcn2 expression was strongly induced in WT mice, but there was no detectable induction in IL-17RA Ϫ/Ϫ or Act1 Ϫ/Ϫ mice, confirming that the regulation of this gene is almost entirely IL-17 dependent in this infection setting (Fig. 1C) . The expression of lcn2 was not statistically different between untreated and cortisone-treated WT mice at day 4. Lipocalin 2 is dispensable for immunity to OPC. Since infection with OPC triggered upregulation of lcn2 in an IL-17-and Act1-dependent manner, we hypothesized that Lcn2 would be important for immunity to oral Candida albicans infection. Accordingly, WT or lcn2 Ϫ/Ϫ mice (27) were subjected to OPC for 5 days, and fungal loads in the oral mucosa were assessed as described above. As controls, we also used IL-23 Ϫ/Ϫ mice (which show the same susceptibility to OPC as IL-17RA Ϫ/Ϫ mice [8] ). As an additional control, lcn2 Ϫ/Ϫ mice were immunosuppressed with high-dose cortisone acetate. Both WT and lcn2 Ϫ/Ϫ mice cleared the infection by day 5. However, cortisone-treated lcn2 Ϫ/Ϫ mice were highly susceptible to disease, and so, to a lesser extent, were IL-23 Ϫ/Ϫ mice ( Fig. 2A) . Weight loss tracked with susceptibility to disease; that is, mice that cleared C. albicans (WT and lcn2 Ϫ/Ϫ mice) exhibited complete weight recovery, whereas IL-23 Ϫ/Ϫ mice or cortisone-treated lcn2 Ϫ/Ϫ mice showed progressive weight loss (Fig. 2B ). In agreement with these findings, histological analysis of tongue tissue stained with periodic acid-Schiff stain (PAS) (to detect yeast) showed that WT and lcn2 Ϫ/Ϫ mice had normal tissue architecture, with no detectable fungal organisms, at day 5. In contrast, IL-23 Ϫ/Ϫ and cortisone-treated lcn2 Ϫ/Ϫ mice showed destruction of the superficial epithelial layer by hyphal and pseudohyphal forms of Candida albicans (Fig. 2C) , in a manner similar to that which we observed previously for cortisone-treated WT mice or IL-17RA Ϫ/Ϫ mice (7). These results indicate that Lcn2, though strongly induced by IL-17 during the course of oral Candida exposure, is not required to mediate fungal clearance.
Lipocalin 2-deficient mice show enhanced resistance to OPC induced by cortisone treatment. Since lcn2 Ϫ/Ϫ mice were not susceptible to OPC, we questioned whether they might show enhanced resistance to infection. Accordingly, we compared the fungal susceptibilities of WT and lcn2 Ϫ/Ϫ mice that were treated with cortisone acetate to induce immunosuppression. As shown, the fungal load in WT mice treated with cortisone was approximately 1 log unit greater than that in lcn2 Ϫ/Ϫ mice treated with cortisone (4.8 ϫ 10 5 compared with 3.72 ϫ 10 4 CFU), a difference that was statistically significant (P, 0.0034) (Fig. 3A) . In agreement with this observation, cortisone-treated lcn2 Ϫ/Ϫ mice did not lose as much weight as cortisone-treated WT mice (Fig. 3B) . Therefore, a deficiency in Lcn2 is associated with significant and reproducible, albeit modest, resistance to OPC.
DISCUSSION
In recent years, it has become clear that IL-17 is a central mediator of immunity to fungi, including C. albicans and other pathogens of fungal origin (30) . The importance of IL-17 in mucocutaneous candidiasis is underscored by discoveries of patients with mutations in genes that impact the generation of Th17 cells (including STAT3, STAT1, and CARD9) or that block IL-17-mediated signaling (including IL17F, IL17RA, and ACT1) (6, 30, 31) . Studies of humans also indicate that the vast majority of Candida-reactive Th cells express IL-17 (32) . However, the downstream mechanisms by which IL-17 confers antifungal immunity are not well defined, and it is important to understand them in order to optimize therapies or intervention strategies for fungal diseases.
IL-17 induces numerous genes that could potentially participate in the immune response to Candida albicans. One of the most strongly induced genes in cell lines and in Candida-infected mucosal tissue encodes Lcn2 (7, 20) . A variety of biological functions have been ascribed to Lcn2, including roles in the control of apoptosis and in tissue development (33, 34) . Lcn2 is also a bacteriostatic factor that binds to soluble ferric siderophores expressed by Gram-negative bacteria. Siderophores help these microbes acquire nutritional iron and are essential for virulence. Consequently, mice lacking Lcn2 are sensitive to E. coli and K. pneumoniae infections (25, 26) . Resistance to Lcn2 also confers a survival advantage on Salmonella enterica serovar Typhimurium (35, 36) . Thus, Lcn2 plays a role in counteracting the survival strategies used by bacteria to obtain iron.
Although Lcn2 is important in immunity to various bacteria, its role in fungal infections is poorly understood. Since lcn2 mRNA expression was strongly upregulated during oral candidiasis in a manner that was almost completely dependent on IL-17 signaling (Fig. 1) (7) , we hypothesized that Lcn2 was required for immunity to OPC. However, Lcn2
Ϫ/Ϫ mice were fully resistant to disease, showing the same kinetics of weight change that occur in WT mice and exhibiting no fungal load or histological evidence for fungal invasion at days 4 to 5 postinfection (Fig. 2) . Our finding stands in contrast to a recent publication by Liu et al. reporting that Lcn2
Ϫ/Ϫ mice are more susceptible to disseminated (bloodstream) candidiasis than WT mice (37) . That report described a chemotactic defect in Lcn2 Ϫ/Ϫ neutrophils, which was proposed to be the basis for their susceptibility to candidemia. Neutropenia is a more important risk factor for systemic candidiasis than for mucocutaneous candidiasis (3), which may explain why Lcn2 deficiency increases susceptibility to systemic but not mucosal C. albicans infections. Although our finding that Lcn2 is not required for immunity to OPC was unexpected, the expression of Lcn2 in a setting where it is dispensable for immunity has a precedent. Lcn2 binds siderophores expressed by Mycobacterium tuberculosis (38) , but Lcn2-deficient mice are not more susceptible to low-dose aerosol infection with M. tuberculosis than wild-type mice. In that setting, Lcn2 acts to constrain T cell activation, and Lcn2 Ϫ/Ϫ mice consequently showed enhanced inflammation, which was associated with increased levels of certain gene products known to be regulated by IL-17, such as G-CSF and CXCL1 (39) . Prompted by this observation, we hypothesized that Lcn2 deficiency might be associated with increased resistance to OPC. Therefore, we compared fungal loads in WT and Lcn2 Ϫ/Ϫ mice subjected to chemical immunosuppression. Indeed, we found that Lcn2 Ϫ/Ϫ mice had fungal burdens approximately 10-fold lower than those of WT mice, a result consistent with the reduced weight loss profile during infection (Fig. 3) .
Why is Lcn2 so strongly upregulated if it is not required for fungal resistance? C. albicans infection induces a strong drive to recruit and expand neutrophils, which is mediated by other IL-17-regulated genes, such as csf3 (encoding G-CSF) and cxcl1, cxcl2, and cxcl5, encoding chemokines that recruit neutrophils and other myeloid cells to the oral mucosa. Lcn2 is expressed strongly in neutrophils as well as in epithelial cells, so its expression in the oral mucosa may simply reflect increased trafficking of neutrophils to the site of infection. C. albicans has a variety of ways to scavenge iron, including extracellular ferric reductases and a siderophore iron transporter system (CaArn1p) (40) . It has been demonstrated recently that Lcn2 does not sequester the C. albicans siderophore (37) . Therefore, it is perhaps not surprising that the absence of Lcn2 does not impair the ability of C. albicans to survive and promote disease.
Fungal diseases are on the rise, as a result of an aging population and increasing use of immunosuppressive therapies for autoimmunity and cancer (4) . Understanding the basis of antifungal immunity is critical for developing vaccines, immunomodulatory strategies, or new treatments for fungal pathogens. The lack of a role for Lcn2 in oral candidiasis underscores the complexity of the antifungal response and sheds light on the differing immune responses to different types of C. albicans-induced infections. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.
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(B) Following infection, Lcn2
Ϫ/Ϫ mice treated with cortisone lose less weight than WT mice treated with cortisone. Mice were weighed daily, and the percentage of change from day 0 relative to infection is indicated.
